A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1
Toxins · 10.11.2026 · 18 (11) · 488
DOI: 10.3390/toxins18110488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, online erschienen am 10.11.2026. Verfasst von Aki Yamaguchi und 9 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAK-ENHI, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Botulism is a fatal disease characterized by flaccid paralysis caused by botulinum neurotoxin (BoNT). In adults, human botulism is currently treated with equine-derived antitoxins, which have provided substantial clinical benefit and remain the mainstay of treatment. However, these equine antitoxin products carry a risk of adverse reactions due to heterologous proteins and have limitations in stable supply. Here, we developed three fully human monoclonal antibodies (HuMAbs)—BT-015, BT-175, and NT-320—against botulinum neurotoxin subtype A1 (BoNT/A1), a major cause of human botulism. BT-015 and BT-175 bound to recombinant LHN, which comprises the catalytic domain (light chain) and the N-terminal translocation domain of the heavy chain, whereas NT-320 bound to the C-terminal receptor-binding domain of the heavy chain (HC). Competition assays further showed that BT-015 and BT-175 recognize largely distinct binding sites within LHN. Each antibody showed neutralizing activity in mice, whereas the three-antibody cocktail provided the greatest protective effect and completely protected mice against the BoNT/A1 medium progenitor toxin complex (M-PTC) under the conditions tested. Moreover, treatment with the cocktail shortly after the onset of clinical signs following oral challenge with the BoNT/A1 large progenitor toxin complex (L-PTC) improved survival and promoted recovery from clinical signs. These findings highlight the therapeutic potential of the HuMAb cocktail for botulism.
Förderung
- Japan Society for the Promotion of Science (JSPS) KAK-ENHI
- Japan Agency for Medical Research and Development
Zitieren
APA
Yamaguchi, A., Matsumura, T., Azuma, M., Suzuki, K., Yutani, M., Akagi, S., Amatsu, S., Kobayashi, N., Takahashi, M., & Fujinaga, Y. (2026). A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1. Toxins, 18(11), 488. https://doi.org/10.3390/toxins18110488
Vancouver
Yamaguchi A, Matsumura T, Azuma M, Suzuki K, Yutani M, Akagi S, et al. A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1. Toxins. 2026;18(11):488. doi:10.3390/toxins18110488
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Aki and Matsumura, Takuhiro and Azuma, Masachika and Suzuki, Kazuhiro and Yutani, Masahiro and Akagi, Sachiyo and Amatsu, Sho and Kobayashi, Nobuhide and Takahashi, Motohide and Fujinaga, Yukako},
title = {A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1},
journal = {Toxins},
year = {2026},
volume = {18},
number = {11},
pages = {488},
doi = {10.3390/toxins18110488}
}
EUVIMED